| dc.creator | Isbell, Michael | |
| dc.creator | Bekker, Linda-Gail | |
| dc.creator | Grinsztejn, Beatriz | |
| dc.creator | Kates, Jennifer | |
| dc.creator | Kamarulzaman, Adeeba | |
| dc.creator | Lewin, Sharon R. | |
| dc.creator | Ngure, Kenneth | |
| dc.creator | Phanuphak, Nittaya | |
| dc.creator | Pozniak, Anton | |
| dc.creator | Grimsrud, Anna | |
| dc.date | 2023-01-19T10:46:55Z | |
| dc.date | 2023-01-19T10:46:55Z | |
| dc.date | 2022 | |
| dc.date.accessioned | 2023-09-26T20:24:37Z | |
| dc.date.available | 2023-09-26T20:24:37Z | |
| dc.identifier | ISBELL, Michael et al. Lessons for the HIV response from structural innovations catalysed by COVID-19. BMJ global health, v. 7, n. 11, p. 1-6, 2022. | |
| dc.identifier | 2059-7908 | |
| dc.identifier | https://www.arca.fiocruz.br/handle/icict/56507 | |
| dc.identifier | 10.1136/bmjgh-2022-010854 | |
| dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/8856270 | |
| dc.description | ⇒ While much has been written on how the HIV response
laid the groundwork for the COVID-19 response, this
analysis examined structural innovations used to respond to COVID-19 and assessed their potential utility
for the future of the HIV response.
⇒ Our analysis indicates certain COVID-19-related
innovations are clearly relevant and have potential
value for the HIV response moving forward.
⇒ Public–private partnerships that catalysed the unprecedented, rapid development of COVID-19 vaccines and the numerous innovations in the design
and conduct of clinical trials that made them more
efficient and reduced burdens on trial participants
have important lessons for the HIV response.
⇒ Experience with COVID-19 diagnostics underscores
the need to bring underused HIV point-of-care diagnostic technologies to scale and increase access to
HIV viral load monitoring.
⇒ COVID-19 also highlighted the importance of enhancing
the timeliness and strategic use of data for HIV-related
decision-making and programmatic adaptations.
⇒ Other COVID-19-related innovations, such as the Access
to COVID-19 Tools Accelerator and COVID-19 Vaccines
Global Access initiative, are less immediately applicable
to HIV, in part due to the success of the HIV response in
developing analogous mechanisms.
⇒ The failure of any manufacturer of a COVID-19 vaccine to use the voluntary licensing mechanism of
the Medicines Patent Pool has slowed vaccination
uptake and provides an important lesson for what
the HIV response ought not to do for future HIV prevention, treatment and cure breakthroughs.
⇒ The global community’s failure to ensure equitable
access to COVID-19 vaccines and treatments highlights the enduring importance of principles of global solidarity and shared responsibility in addressing
global health challenges. | |
| dc.format | application/pdf | |
| dc.language | eng | |
| dc.publisher | BMJ | |
| dc.rights | open access | |
| dc.subject | COVID-19 | |
| dc.subject | HIV | |
| dc.subject | Public Health | |
| dc.title | Lessons for the HIV response from structural innovations catalysed by COVID-19 | |
| dc.type | Article | |
